192 related articles for article (PubMed ID: 35365123)
1. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
[TBL] [Abstract][Full Text] [Related]
2. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
[TBL] [Abstract][Full Text] [Related]
7. Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study.
Chang J; Xu M; Wang C; Huang D; Zhang Z; Chen Z; Zhu X; Li W
Clin Colorectal Cancer; 2022 Dec; 21(4):347-353. PubMed ID: 35941028
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
Clin Colorectal Cancer; 2018 Sep; 17(3):198-205. PubMed ID: 29866615
[TBL] [Abstract][Full Text] [Related]
9. HER2-Positive Metastatic Colorectal Cancer.
Robinson HR; Messersmith WA; Lentz RW
Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
[TBL] [Abstract][Full Text] [Related]
10. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
[TBL] [Abstract][Full Text] [Related]
13. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
Xu T; Wang X; Xin Y; Wang Z; Gong J; Zhang X; Li Y; Ji C; Sun Y; Zhao F; Huang D; Bai Y; Li J; Shen L
Cancer Res Treat; 2023 Apr; 55(2):626-635. PubMed ID: 36550683
[TBL] [Abstract][Full Text] [Related]
15. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
16. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
17. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract][Full Text] [Related]
18. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
19. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
